Crop 0 0 1200 628 0 Featuredimage2 — Bodhi Addiction Treatment & Wellness

Ketamine rarely comes up first on an admissions call. People mention alcohol, pills, or stimulants, and ketamine surfaces ten minutes in, usually described as “not really the problem” or “something my doctor started.” This guide covers what residential treatment actually does when ketamine is part of the picture: how use is assessed, why there is no detox medication for it, what happens to the bladder, how a legitimate ketamine prescription is handled, and exactly what to tell admissions so the first week is planned correctly. If you want to talk it through now, call (877) 328-1968.

The Short Version: How Ketamine Is Classified and Treated

Ketamine is a Schedule III controlled substance under federal law, approved as an anesthetic, and there is no FDA-approved medication for treating ketamine use disorder. Esketamine (Spravato), the FDA-approved nasal spray for treatment-resistant depression, can only be given in a certified healthcare setting, where the patient is monitored for at least two hours after each dose and cannot take the medication home. So when someone has ketamine at home in powder, liquid, or lozenge form, it is either illicit, diverted, or prescribed off-label by a telehealth or clinic prescriber, and residential treatment for problematic ketamine use relies on medical monitoring, symptom management, and behavioral therapy rather than a replacement medication.

How Admissions Decides Whether Ketamine Use Is a Disorder

In the DSM-5, ketamine falls under the phencyclidine-type substances. A use disorder is diagnosed when at least two of the listed criteria occur within a 12-month period: using more than intended, failed attempts to cut down, cravings, giving up activities, continued use despite physical or psychological harm, tolerance, and so on. One difference matters for planning: unlike alcohol or opioids, the criteria list does not include a defined withdrawal syndrome. That does not mean stopping is easy. It means the difficult part is usually psychological rather than a predictable physical withdrawal curve.

A clinician will also use the ASAM Criteria to decide whether residential treatment is the right level of care, looking at medical risk, mental health, readiness, and how safe the home environment is.

Why Ketamine Use Escalates

From the admissions side, these are the patterns that come up again and again. They are clinical observations, not a checklist for self-diagnosis.

  • Fast tolerance: The dissociative effect fades with repeated use, so people take larger amounts or use more often to get the same distance from their thoughts.
  • Dissociation as relief: For someone with depression, anxiety, or trauma, the detached state can feel like the first break in months, which makes it hard to see the use as a problem.
  • The prescription bridge: Some people start with ketamine for depression and begin taking extra doses between sessions or buying more when the supply runs out.
  • Short effect, repeated dosing: The effects wear off relatively quickly, which encourages several doses in a single night.
  • Mixing with depressants: Ketamine is often combined with alcohol or benzodiazepines, which raises the risk of dangerous sedation and slowed breathing.

What the First Week Actually Looks Like

Because there is no standard ketamine detox protocol, the first days in residential care are about watching closely and treating what shows up. People commonly describe low mood, poor or broken sleep, fatigue, irritability, strong cravings, and a flat, foggy feeling sometimes described as “not being back in my body yet.” Families often notice the person sleeping far more than usual early on, then becoming restless and anxious later in the week.

Mood is the part the clinical team watches most closely. When ketamine has been masking depression, that depression can return quickly once use stops. Staff will check in on mood and safety daily and coordinate with psychiatry. If co-occurring depression or anxiety is significant, integrated mental health treatment runs alongside the substance use work rather than after it. The National Institute of Mental Health notes that substance use disorders and mental health conditions frequently occur together and are best treated together.

A safety note that matters more than the ketamine itself: if ketamine has been used alongside daily alcohol or benzodiazepines, withdrawal from those substances can cause seizures and can be life-threatening. That withdrawal requires medical supervision. Do not stop alcohol or benzodiazepines suddenly on your own before admission. Tell admissions exactly how much and how often, so the medical team can plan a supervised taper.

The Bladder Problem Nobody Mentions on the Phone

Regular ketamine use is linked to damage to the bladder and urinary tract, sometimes called ketamine-associated uropathy or ketamine cystitis. Symptoms include needing to urinate very often, urgency, pain when the bladder fills or empties, and blood in the urine. Many people have lived with these symptoms for months and assume they are a recurring urinary tract infection that antibiotics never quite clear.

Stopping ketamine is the most important step, and some people see improvement after they stop, but severe or long-standing damage may need a urologist. A residential medical team can order a urine test, track symptoms, and arrange a referral. Visible blood in the urine, inability to urinate, fever, or severe pain needs prompt medical evaluation, not a wait-and-see approach.

If Your Ketamine Is Prescribed

A legitimate prescription does not disqualify anyone from treatment, and it does not have to be hidden. What admissions needs is the full picture: who prescribes it, the dose, the form, how often it is taken, and whether actual use matches the prescription. If it does match, the medical team will usually contact the prescriber, with your written consent, to decide together whether to pause, continue, or replace it with a different depression treatment during the stay. If use has gone beyond the prescription, say so plainly. It changes the treatment plan, and it is far better for the team to know on day one than to find out on day five.

Do not stop a prescribed depression treatment abruptly before admission without talking to the prescriber first, because mood can drop quickly.

What to Tell Admissions: A Checklist You Can Use Today

Before you or your loved one calls, write these down. It takes about ten minutes and makes the intake assessment much more accurate.

  1. Form and route: powder (snorted), liquid, lozenge, injection, or prescribed nasal or clinic treatment.
  2. Amount and frequency: a typical day or weekend, and the date and time of last use.
  3. Everything else used with it: alcohol, benzodiazepines, opioids, stimulants, cannabis, with amounts for each.
  4. Bladder symptoms: how many times a day you urinate, any pain, and any blood. If you can, keep a simple tally for the next 24 hours.
  5. Mental health history: diagnoses, current medications, and any past suicide attempts or recent thoughts of suicide.
  6. Prescriber details: name, clinic, and phone number if ketamine or esketamine is prescribed.
  7. Insurance card: front and back. You can start a check through our insurance verification page.

Then ask admissions this one question directly: “How will your medical team monitor mood and bladder symptoms in the first week, and who coordinates with my prescriber?” A program that has thought about ketamine will have a specific answer.

For Families: What You Can Do Right Now

Families often see the bathroom trips, the long periods of staring or seeming disconnected, and the mood crashes before the person admits there is a problem. You do not need to prove anything to start a conversation with admissions. Write down what you have observed and when, and call. If the person is unsafe, unresponsive, or talking about suicide, call 911 or the 988 Suicide & Crisis Lifeline by calling or texting 988. For free, confidential treatment referrals at any hour, the SAMHSA National Helpline is available, and the National Institute on Drug Abuse maintains research-based information on substances and treatment.

Getting Started in Northern California

Ketamine use is treatable, and recovery does not depend on a medication that does not exist. It depends on a careful first week, honest information at intake, and treatment that addresses whatever the ketamine was covering up. Our admissions team can walk you through the assessment, insurance, and next steps. Call (877) 328-1968 to speak with someone today.

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Withdrawal from alcohol or benzodiazepines can be dangerous and should only happen under medical supervision. If you or someone you know is in crisis, call or text 988 or call 911.

Prescription bottle with pills on a counter — residential rehab for chronic pain and opioid use disorder

Benzodiazepines such as alprazolam (Xanax), clonazepam (Klonopin), lorazepam (Ativan), and diazepam (Valium) are some of the most commonly prescribed medications in the country, and many people who end up needing residential treatment started taking them exactly as a doctor directed. That is part of what makes the admissions process for benzodiazepine dependence different from almost any other substance. This guide explains how residential programs approach it, why the timeline is slower than people expect, and the specific information admissions will ask you for.

The Short Answer: Benzodiazepine Withdrawal Is Never Done Cold Turkey

Stopping a benzodiazepine abruptly after regular use can cause seizures, severe rebound anxiety, confusion, and in some cases delirium. In September 2020 the U.S. Food and Drug Administration required the boxed warning on every benzodiazepine to be updated to address abuse, misuse, addiction, physical dependence, and withdrawal reactions, and that warning states that abrupt discontinuation or rapid dose reduction can cause serious, potentially life-threatening withdrawal. For that reason, anyone who has been taking a benzodiazepine daily for more than a few weeks should only reduce or stop it under medical supervision, usually with a gradual taper that is planned before admission rather than improvised after it.

If you are worried about yourself or someone else right now, call (877) 328-1968 to talk through options, or call 911 if someone is having a seizure, is unresponsive, or is confused and agitated after stopping a medication.

Why Benzodiazepine Withdrawal Is Medically Different

Most people know that opioid withdrawal is miserable. Fewer people know that benzodiazepine and alcohol withdrawal are the two that can be dangerous on their own. The reasons are worth understanding because they shape every decision admissions makes.

  • GABA adaptation: Benzodiazepines enhance the brain’s main calming signal, so with daily use the brain turns its own calming system down, and removing the drug suddenly leaves the nervous system overexcited.
  • Seizure threshold: That overexcited state lowers the seizure threshold, which is why both benzodiazepine and alcohol withdrawal carry seizure risk and require medical supervision.
  • Half-life differences: Short-acting drugs such as alprazolam can produce withdrawal within a day or two of the last dose, while long-acting drugs such as diazepam may not show withdrawal for several days, which can create false reassurance.
  • Combination risk: Benzodiazepines combined with alcohol or opioids increase the risk of slowed breathing and overdose, a combination the National Institute on Drug Abuse specifically warns about.
  • Counterfeit pills: Pills bought outside a pharmacy that look like alprazolam may contain other sedatives or fentanyl, so the actual dose a person has been taking is often unknown.

What Week One Actually Looks Like

People are often surprised that the first week of residential care for benzodiazepine dependence can feel quieter than they feared. When a taper is managed well, the medical team usually stabilizes the person on a known dose first, often converting to a longer-acting benzodiazepine so blood levels stay steadier, and then begins reducing slowly. The common complaints in the first days are poor sleep, a jittery or “wired” feeling, irritability, and heightened sensitivity to light and sound. Families often notice that their loved one is more anxious than before admission, and they worry that treatment is making things worse. In most cases this is the expected rebound, not a sign that the plan has failed, and it is something the clinical team is watching for.

What a residential setting adds is that the person is not managing those symptoms alone at home with a pill bottle in the cabinet. Group therapy, structured sleep routines, and skills for managing anxiety without medication begin while the taper is still underway, so that by the time the dose reaches zero, the person has already practiced coping tools.

Why the Taper Often Takes Longer Than the Stay

Here is the inconvenient operational truth that families are rarely told up front: for someone who has taken a benzodiazepine daily for months or years, a medically sensible taper can last longer than a typical residential stay. Current guidance from the American Society of Addiction Medicine and partner organizations favors gradual, individualized reductions over rapid detox, and the pace is adjusted to how the person responds. That means the residential program often begins the taper, gets the person stable and engaged in recovery work, and then hands the rest of the taper to an outpatient prescriber with a written plan.

From the referral side, the most common breakdown we see is not in the residential phase. It is the handoff. A person leaves residential care partway through a taper without a confirmed appointment, runs out of medication, and either stops abruptly or returns to a non-pharmacy supply. Before discharge, ask the program to name the outpatient prescriber who will continue the taper and confirm the first appointment date in writing. Our outpatient treatment options are built to continue that kind of plan.

What to Tell Admissions: A Checklist You Can Complete Today

Admissions teams need accurate information to decide whether a person needs a medically monitored detox first or can taper safely inside a residential treatment program. Before you call, write down the following. It takes about fifteen minutes and it is the single most useful thing you can do to speed up placement.

  1. Every benzodiazepine, by name: Include ones taken “only as needed” and sleep medications such as zolpidem (Ambien), which act on the same system.
  2. Actual daily amount: What is really being taken, not what the label says. If the amount varies, give the highest recent day.
  3. Time of the last dose: This tells the medical team where the person is on the withdrawal timeline.
  4. Source: Pharmacy, a friend’s prescription, or pills bought online or on the street. Non-pharmacy pills change the risk assessment because of counterfeit content.
  5. Alcohol and opioid use: Any combination changes the level of medical monitoring required.
  6. Seizure history: Any past seizure, including during a previous attempt to stop.
  7. The prescriber’s name and phone number: The program will want to coordinate, with your written consent.

In California, prescribers and pharmacists can check the state prescription drug monitoring database, known as CURES, to see controlled-medication fills. You can also ask your own pharmacy for a printout of your fill history before you call. Bringing that printout to the admissions conversation removes guesswork about doses and dates.

Questions to Ask Before You Choose a Program

Not every residential program is set up to manage benzodiazepine withdrawal on site. Ask these questions directly:

  • Do you have 24-hour nursing and a prescriber who can manage a benzodiazepine taper, or will I need a separate detox first?
  • How do you decide the starting dose and the pace of reduction?
  • What happens if withdrawal symptoms become severe at night?
  • How will the taper continue after discharge, and who will prescribe it?
  • Will my insurance treat detox and residential care as one authorization or two? (Our team can help you verify insurance benefits before admission.)

The SAMHSA National Helpline is another free, confidential resource for finding treatment, available 24 hours a day.

A Note for Families

If your loved one takes a benzodiazepine every day, please do not hide, flush, or ration their medication to force the issue. Taking the supply away abruptly can trigger the same dangerous withdrawal described above. The safer path is to encourage a conversation with their prescriber or with an admissions team, and to help gather the information on the checklist. Many people who depend on benzodiazepines feel deep shame because they “only did what the doctor said.” Leading with that understanding, rather than with accusation, tends to make the first call easier.

Getting Help in Northern California

Bodhi Addiction Treatment & Wellness helps individuals and families in Santa Cruz County and across Northern California find the right level of care, including medically supervised withdrawal and residential treatment. If you or someone you love is ready to talk about a safe plan for stopping benzodiazepines, call (877) 328-1968. If you are in emotional crisis, call or text 988 to reach the 988 Suicide & Crisis Lifeline.

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Do not stop, reduce, or change any medication, including a benzodiazepine, without guidance from a qualified healthcare provider. Benzodiazepine and alcohol withdrawal can cause seizures and require medical supervision. If you are experiencing a medical emergency, call 911.

Mental Health Treatment | Bodhi Addiction & Wellness

Most people calling about residential treatment ask about insurance, length of stay and what to pack. Far fewer ask the question that most often causes a problem on admission day: what happens to the medications I already take? Blood pressure pills, an antidepressant, an inhaler, a stimulant for ADHD, a sleep aid, a benzodiazepine prescribed years ago. Every one of them has to be accounted for before the first night, and the process that does it has a name: medication reconciliation.

This guide explains how that process works in a residential setting, why controlled prescriptions are handled differently, and exactly what to have ready before you call admissions.

What Medication Reconciliation Means in Residential Treatment

Medication reconciliation in residential addiction treatment is the process of comparing every medication a person reports taking, including prescriptions, over-the-counter products and supplements, against pharmacy records and prescriber information, so the medical team can decide on the first day which medications continue unchanged, which are adjusted, which are tapered under supervision, and which are paused. It is completed at intake and repeated at discharge, and it depends heavily on how complete and accurate the list the person brings with them is.

In practice, the medical team is answering four questions for each item: Is it actually prescribed to this person? Is it being taken as prescribed? Does it interact with withdrawal management or with medications for addiction treatment? And is stopping it suddenly safe?

Why Controlled Prescriptions Get a Closer Look

Most routine medications, such as those for blood pressure, thyroid, diabetes or asthma, simply continue. The closer review is reserved for medications that can cause dependence or that change how withdrawal behaves.

Benzodiazepines: stopping them abruptly after regular use can cause seizures, so any change must be a supervised taper, never a sudden stop.

Opioid pain medications: combined with benzodiazepines or alcohol they raise the risk of dangerously slowed breathing, which affects how both are managed.

Stimulants prescribed for ADHD: the team weighs the documented diagnosis against current substance use before deciding whether to continue, adjust or pause.

Sleep medications and sedating supplements: these can stack with withdrawal medications and with each other, so the full list matters, including products bought without a prescription.

The U.S. Food and Drug Administration (FDA) has addressed the risks of benzodiazepine and opioid prescriptions directly. In August 2016 it required boxed warnings, its most prominent safety label, on opioid and benzodiazepine products about the dangers of using them together. In September 2020 it required the boxed warning on all benzodiazepines to be updated to describe the risks of misuse, addiction, physical dependence and withdrawal reactions. Those two dated label changes are a large part of why residential addiction treatment programs handle these prescriptions with extra care rather than continuing them automatically. The National Institute on Drug Abuse (NIDA) also publishes plain-language information on prescription medication misuse that families may find useful.

A Safety Point That Overrides Everything Else

If you or your loved one drinks heavily every day, or takes a benzodiazepine daily, do not stop on your own in the days before admission to “get a head start.” Withdrawal from alcohol and from benzodiazepines can cause seizures and, in severe cases, can be life-threatening. Medical supervision is required. The safest plan is usually to continue as you are, report your use honestly, and let the medical team manage the transition. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) describes alcohol withdrawal as a condition that can require medical treatment, and the American Society of Addiction Medicine (ASAM) publishes clinical guidelines for managing it.

If you are unsure whether it is safe to wait until admission, call us at (877) 328-1968 and ask to speak with someone about it before you change anything.

What We See Go Wrong on Admission Day

From years of admissions work in Northern California, the medication problems we see are rarely dramatic. They are logistical, and almost all of them are preventable:

  • Pills in a pill organizer or a plastic bag. Medications that are not in the original pharmacy-labeled container usually cannot be identified and verified, so they cannot be given until a replacement is obtained. That can mean a delay of a day or more for a medication the person depends on.
  • A list from memory. People commonly forget the inhaler, the eye drops, the once-weekly injection, or the supplement they take every night. Each omission is a gap in the medical picture.
  • Prescriptions from several prescribers. When a primary care doctor, a psychiatrist and a pain specialist each prescribe something, no single office has the whole list. The treatment team may be the first to see it all together.
  • Underreporting use. Saying “two drinks a night” when it is closer to a bottle, or “as prescribed” when it is twice the dose, does not change what the body will do in withdrawal. It only means the plan is built on the wrong numbers.

None of these reflect badly on the person. They are what happens when someone is preparing for treatment under stress. They are also easy to fix in advance.

What to Do Before You Call Admissions

Here is a short checklist you can complete today, before the admissions call or before admission day:

  1. Gather every bottle. Put every prescription, over-the-counter medication and supplement you have taken in the last 30 days on one table, in its original labeled container.
  2. Write one list. For each item, write the name, the dose, how often you actually take it, the prescriber, and the pharmacy. “Actually” matters more than “supposed to.”
  3. Call your pharmacy. Ask for a printed medication history. Most pharmacies can provide one, and it often catches items people forget.
  4. Flag the controlled ones. Circle anything that is a benzodiazepine, an opioid, a stimulant or a sleep medication, and note how long you have taken it.
  5. Ask these three questions on the admissions call: “Which of my medications will continue on day one?” “If a medication needs to be tapered, who sets the schedule?” “If something I take is not continued, will my prescriber be told?”

Bring the list, the bottles and the pharmacy printout on admission day. Admissions can tell you about any program-specific rules, such as how medications are stored and dispensed. You can start that conversation at (877) 328-1968.

What Happens After Intake

Once the medical team has the list, decisions are typically made in the first hours or day. Continued medications are usually stored and dispensed by staff rather than kept by the person. Medications that are tapered follow a written schedule. If a medication for addiction treatment, such as buprenorphine or naltrexone, is part of the plan, it is checked against everything else on the list first.

Reconciliation happens again at discharge. That second pass is just as important: the person should leave with a single, current list, a clear note on anything that was changed and why, and confirmation that the outpatient prescriber has been informed. If you are planning the step after residential care, our pages on partial hospitalization and outpatient treatment explain how care typically continues. You can also read about our approach to residential treatment.

For Families Helping With Preparation

Families often end up doing the practical work: collecting bottles from the bathroom cabinet, calling the pharmacy, finding the psychiatrist’s phone number. That help is valuable. It works best when the person entering treatment is part of it, because only they know what they actually take and how often. If your loved one is reluctant to share details with you, encourage them to share them directly with admissions instead. The goal is an accurate list, not who compiles it.

For confidential, free help finding treatment and support at any hour, the SAMHSA National Helpline is available 24 hours a day, 365 days a year, at 1-800-662-4357. If you or someone you love is in crisis or thinking about suicide, call or text 988. In an emergency, call 911.

Talk to Bodhi Before You Change Anything

If you are preparing for residential treatment and are unsure what to do with a current prescription, the most useful step is a conversation before admission, not on the day. Call Bodhi Addiction Treatment at (877) 328-1968 to talk through your medications, your use and what to bring.

This article is for educational purposes only and is not medical advice. Do not start, stop or change any medication without guidance from a qualified healthcare provider. Withdrawal from alcohol or benzodiazepines can be dangerous and requires medical supervision.

Nurse reviewing medical records at a computer during an overnight shift in a residential detox unit

Families calling about residential treatment for opioid use often ask one question first: “Will they keep him on his medication?” The second question, usually asked later and with more worry, is “If she isn’t on anything yet, can they start it there?” Those are two different admissions questions, and programs answer them differently. This guide explains how buprenorphine is started in a residential setting, what the COWS score measures, and exactly what to confirm with admissions before the intake date.

Starting Buprenorphine Is a Timed Medical Step, Not a Prescription Handed Over

Buprenorphine is one of the medications for opioid use disorder recognized by the National Institute on Drug Abuse (NIDA) and addressed in the American Society of Addiction Medicine (ASAM) National Practice Guideline. Starting it, a process clinicians call induction or initiation, is timed. Because buprenorphine binds tightly to opioid receptors but activates them only partially, taking the first dose while full-agonist opioids such as fentanyl, heroin or oxycodone are still occupying those receptors can push a person abruptly into withdrawal. That is called precipitated withdrawal, and avoiding it is the main reason the first dose is scheduled around a measured withdrawal score rather than a clock.

In practice, the first day in a residential program that starts buprenorphine on-site looks like this: the person arrives, completes the medical intake, and is then observed. Nursing staff reassess withdrawal on a schedule. When the score shows enough withdrawal, the prescriber approves a first dose, and the person is reassessed again afterward. Many people describe that first wait as the hardest part of week one: restless legs, yawning, gooseflesh, a running nose and the feeling that time has stopped. Knowing in advance that the wait is deliberate makes it easier to get through.

What the COWS Score Measures

The Clinical Opiate Withdrawal Scale (COWS) is an 11-item clinician-rated checklist scored from 0 to 48, used to measure opioid withdrawal before and after a buprenorphine dose. A nurse rates observable signs including resting pulse, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, gastrointestinal upset, tremor, yawning, anxiety or irritability, and gooseflesh. The commonly used bands are 5 to 12 for mild withdrawal, 13 to 24 for moderate, 25 to 36 for moderately severe, and above 36 for severe. Each program’s prescriber sets the score at which a first dose is given, so families should ask for that program’s threshold rather than assume one.

The score matters because it turns “I feel terrible” into something a prescriber can act on safely. It also gives the person in treatment something concrete: a number that is moving, which tells them the plan is working.

Why Fentanyl Changed the First Few Days

Clinicians across the field have adjusted induction practices as fentanyl has replaced heroin and pills in much of the street supply. The reasons are worth understanding before admission:

  • Fat-tissue storage: Fentanyl is highly fat-soluble and can be released from body tissue for longer than its short half-life suggests, so withdrawal may build more slowly and unevenly.
  • Unknown supply: Street pills sold as oxycodone or other opioids often contain fentanyl, so the last-use history a person gives may not reflect what they actually took.
  • Precipitated withdrawal risk: Dosing too early is more likely when fentanyl is still active, which is why some prescribers wait for a higher score or use alternative starting approaches.
  • Mixed substances: Fentanyl in the supply is frequently combined with other sedatives, which changes how a medical team monitors the first 24 to 72 hours.

Some prescribers now use lower-dose or “micro-induction” starts for selected patients, where small buprenorphine doses overlap with the existing opioid for several days. Whether a program offers that option, and for whom, is a clinical decision made by its prescriber. It is a fair question to ask.

Safety: Alcohol and Benzodiazepines Change the Plan

Opioid withdrawal is extremely uncomfortable but is rarely life-threatening on its own in otherwise healthy adults. Alcohol and benzodiazepine withdrawal are different: both can cause seizures and other dangerous complications, and both require medical supervision. Anyone who uses alcohol daily or takes benzodiazepines such as alprazolam, clonazepam or lorazepam, prescribed or not, should never stop abruptly, and must tell admissions about that use before the intake date. Combining opioids with alcohol or benzodiazepines also raises overdose risk. If you are worried someone has overdosed, call 911 immediately. For confidential treatment referral, the SAMHSA National Helpline is available 24 hours a day at 1-800-662-4357.

The Operational Truth: Not Every Residential Program Starts Buprenorphine On-Site

From placement work across our network, this is the gap families most often miss. Some residential programs will continue buprenorphine for someone who arrives already on a stable dose but do not start it on-site. Others start it routinely. Some accept people on methadone only if a dosing arrangement with an opioid treatment program can be made in advance, since methadone for opioid use disorder is dispensed through federally certified clinics. A program’s website rarely spells this out. The answer usually lives with the medical director, and the only reliable way to get it is to ask directly.

A related change helps. Since the Consolidated Appropriations Act of 2023 removed the federal “X-waiver” requirement, any clinician with a standard DEA registration that includes Schedule III can prescribe buprenorphine for opioid use disorder. That widened who can prescribe, but it did not make every residential program set up to manage an on-site start. Staffing, nursing coverage overnight and the program’s medical model still decide that.

Five Questions to Ask Admissions Before the Intake Date

Write these down and ask them on the next admissions call. Ask for the answers in writing if you can.

  1. Do you start buprenorphine on-site, or only continue it? If only continue, ask where the person would be inducted first and how the handoff works.
  2. Who is the prescriber, and how often are they available? Ask whether a prescriber can approve a dose overnight or on a weekend.
  3. What COWS score do you use before the first dose, and how often is it rechecked? A clear answer here is a good sign of an organized medical process.
  4. What is your plan for fentanyl exposure? Ask whether lower-dose starts are available and how precipitated withdrawal is managed if it happens.
  5. How does the prescription continue after discharge? Ask who writes the first outpatient prescription and whether a follow-up appointment is booked before the person leaves. A gap of even a few days after discharge is a known risk period.

If you have not yet confirmed coverage, run a benefits check at the same time; our insurance verification page explains what that check tells you. You can also call our team at (877) 328-1968 and we will help you put these questions to the programs you are considering.

What Families Usually Notice in the First Week

Families often expect the person they love to sound better on the first phone call. Sometimes they do. More often, the first call comes on day two or three and sounds flat or irritable, which is consistent with a body adjusting to a new medication and a structured schedule. By the end of the first week, many people report sleeping more normally and thinking less about using. That is the stabilization a residential treatment setting is designed to protect, so that therapy, family sessions and discharge planning can do their work.

Medication is not a shortcut around treatment, and it is not a substitute for one. It is one part of a plan, and it works best when the plan around it is clear before admission day.

Talk With Someone Who Knows the Programs

Bodhi Addiction Treatment & Wellness helps individuals and families in Northern California and beyond find residential programs that match their medical needs, including whether buprenorphine can be started or continued on-site. Learn more about our founder and clinical reviewer, Jonathan Beazley, CADC-CAS, M-RAS, CCMI-i, or call (877) 328-1968 to talk through your options today.

This article is for educational purposes only and is not medical advice. Medication decisions, including whether and when to start buprenorphine, must be made by a licensed prescriber who has evaluated the individual. Do not stop alcohol, benzodiazepines or any prescribed medication without medical supervision. If you or someone you know is in immediate danger, call 911. For a mental health or substance use crisis, call or text 988.

Prescription bottle with pills on a counter — residential rehab for chronic pain and opioid use disorder

When someone calls our admissions line about alcohol or opioids, a benzodiazepine prescription often comes up almost as an afterthought: “I also take Xanax for sleep,” or “My doctor has had me on clonazepam for years.” That detail changes the admission plan more than almost anything else on the intake form. Benzodiazepines cannot be stopped the way many people expect, and the schedule for coming off them is set by clinical guidance, not by how long a residential stay happens to last.

This post walks through how a benzodiazepine taper is actually planned in residential treatment, what the published guidance says about pace, and what you should confirm with a program before you arrive.

Why Benzodiazepines Are Handled Differently at Admission

Benzodiazepines, including alprazolam (Xanax), clonazepam (Klonopin), lorazepam (Ativan), and diazepam (Valium), act on the brain’s GABA system. With daily use over weeks or months, the brain adapts. Remove the medication suddenly and that adaptation is left unopposed.

Safety first: stopping a benzodiazepine abruptly after regular use can cause withdrawal seizures, which can be life-threatening. The same is true of alcohol. Anyone who has been using benzodiazepines or alcohol daily should not stop on their own, cut down sharply before a bed opens, or “detox at home” without medical supervision. If you are in that situation now, call us at (877) 328-1968 before changing anything.

The mechanism matters because it explains why programs ask so many questions on the first call. In our admissions work, the families who are most surprised are those whose loved one was prescribed the medication legitimately. Dependence is a physical adaptation, and it can develop whether the prescription was followed exactly or not. The National Institute on Drug Abuse describes this distinction between physical dependence and addiction in its overview of prescription medicine misuse.

What the Published Guidance Says About Taper Pace

In 2025, the American Society of Addiction Medicine and a group of partner medical societies released a joint clinical practice guideline on benzodiazepine tapering. It is the reference point most clinicians now use, and it is the document worth asking a program about by name.

A benzodiazepine taper for someone with long-term daily use is usually measured in weeks to months, not days. The joint clinical practice guideline on benzodiazepine tapering, published in 2025 by the American Society of Addiction Medicine and partner medical societies, describes a typical starting pace of dose reductions of about 5 to 10 percent every 2 to 4 weeks, and generally advises against reductions larger than 25 percent in any 2-week period. That means a person entering a 30- to 45-day residential program on a daily benzodiazepine will often still be tapering at discharge, and the discharge plan needs a named prescriber to continue the schedule.

Pace is individualized. The guideline describes adjusting speed based on how the person tolerates each step, and pausing when symptoms are significant. Some people move faster under close supervision; some need much longer. You can read the guideline summary through ASAM’s clinical guidelines page.

The U.S. Food and Drug Administration added a boxed warning to all benzodiazepines in 2020 covering misuse, dependence, and withdrawal reactions, including the risk of abrupt discontinuation. That warning is one reason prescribers have become more cautious about both starting and stopping these medications quickly.

What Drives the Taper Schedule

When our clinical team builds a taper plan, these are the factors that shape it:

  • Duration of use: months or years of daily use generally call for a slower taper than a few weeks of use.
  • Dose and drug: short-acting drugs like alprazolam can produce sharper swings between doses than longer-acting ones, which is why some prescribers convert to a longer-acting benzodiazepine before reducing.
  • Alcohol or other sedatives: combined use of alcohol and benzodiazepines raises withdrawal risk and requires more intensive medical monitoring.
  • Seizure history: any prior withdrawal seizure moves the plan toward a slower, more closely supervised schedule.
  • Co-occurring anxiety or insomnia: the original reason for the prescription does not go away during a taper, so it needs its own treatment plan, often therapy-based.
  • Opioid use or medication for opioid use disorder: the combination of opioids and benzodiazepines increases overdose risk, and coordination between prescribers is essential. The CDC addresses this risk in its overdose prevention resources.

What the First Weeks Actually Look Like

People expect withdrawal to feel like a single hard week. With a properly paced taper, it is usually quieter and longer than that. In the early reductions, clients commonly describe rebound anxiety, lighter or broken sleep, irritability, and a sense of being “on edge” in the evening. Some notice sensitivity to light or sound. Families on visiting days often say their loved one seems more anxious than before treatment, and they worry the program is not working.

That is often what a taper feels like when it is working. The nervous system is readjusting step by step, and each reduction is followed by a period of settling before the next one. This is where residential care earns its place: nursing staff can watch vital signs and symptoms daily, the prescriber can hold a step if needed, and the person is learning non-medication tools for anxiety and sleep in real time, during the exact hours when the old medication used to do that job.

The inconvenient truth from the admissions side is that the hardest conversation is often not about the drug at all. It is telling someone that their benzodiazepine taper will likely continue after they leave our residential program, and that the most important document they take home may be the outpatient prescriber’s appointment, not the discharge summary.

Five Things to Confirm Before Admission

If you or a family member takes a benzodiazepine daily, ask these questions on the admissions call. Write down the answers.

  1. Who manages the taper? Ask for the role of the person who will set and adjust the schedule, such as a physician or psychiatric nurse practitioner, and how often they see clients.
  2. Is the program medically equipped for sedative withdrawal? Ask what level of medical monitoring is available on site and what happens if symptoms escalate. Our residential treatment page explains how care is structured.
  3. Bring every prescription bottle. Bring the actual bottles, with current labels, plus the name and phone number of the prescribing doctor. Today, check the label: write down the drug name, dose, and how many tablets are taken each day. That single list speeds up the medical assessment.
  4. What happens to the taper at discharge? Ask whether the program coordinates a hand-off to an outpatient prescriber and whether that appointment is booked before you leave.
  5. What does insurance cover? Medically monitored withdrawal management may be billed differently than residential care. You can start with a confidential insurance verification.

Do not reduce your dose in the days before admission to “get a head start.” A sudden cut while you wait for a bed is exactly the kind of change that carries seizure risk.

How We Approach This at Bodhi

At Bodhi Addiction Treatment in Northern California, benzodiazepine tapers are planned individually, with medical oversight and a discharge plan that names who continues the schedule. Our clinical approach reflects the practice experience of our founder, Jonathan Beazley, CADC-CAS, M-RAS, CCMI-i, and our team’s work with clients managing both substance use and the anxiety that often came before it.

If you are unsure whether a current prescription affects your admission, the fastest step is to ask. Call (877) 328-1968 and have the prescription label in front of you. If you need help finding treatment anywhere in the country, SAMHSA’s National Helpline is free, confidential, and available 24 hours a day at 1-800-662-4357. If you are in crisis or thinking about harming yourself, call or text 988.

This article is for educational purposes only and is not medical advice. Do not start, stop, or change the dose of any medication without guidance from a qualified healthcare provider. Benzodiazepine and alcohol withdrawal can be dangerous and require medical supervision. If you are experiencing a medical emergency, call 911.

IV drip on a stainless steel stand — 5-day medical detox in residential rehab

Very few people arrive at residential treatment saying “I have an opioid use disorder.” Far more often, the sentence starts somewhere else: a back injury in 2019, a shoulder surgery, an autoimmune condition, a car accident that never fully resolved. The prescription was legitimate. The pain was real. And somewhere in the years that followed, the line between treating pain and needing the medication stopped being visible from the inside.

This is one of the harder presentations in addiction medicine, because the two problems argue with each other. Treat the pain aggressively and you may feed the use disorder. Remove the opioids and you may leave someone in genuine physical distress with no plan. People in this situation are often bounced between a pain clinic that will not manage addiction and a program that will not manage pain. Both problems are treatable, at the same time, by the same team.

Why Pain and Opioid Use Disorder Get Tangled Together

Two things happen over months and years of opioid therapy that make this predictable rather than unusual. The first is tolerance: the same dose does less, so the dose climbs, and the climb feels medically justified because the pain is genuinely still there. The second is that opioid withdrawal itself hurts. Muscles ache, joints throb, the nervous system turns up its sensitivity. So a person tapering down does not experience “less medication” — they experience their original pain plus withdrawal pain, arriving together, and reasonably conclude the medication was the only thing working.

There is also a phenomenon clinicians watch for called opioid-induced hyperalgesia, in which long-term opioid exposure appears to increase sensitivity to pain rather than reduce it. How often it occurs, and how much it contributes in any individual case, is still being studied. But it is one reason some people report that their pain is more manageable several months after coming off high-dose opioids than it was while on them — a result that surprises almost everyone who experiences it. The National Institute on Drug Abuse maintains accessible overviews of how opioid tolerance and dependence develop, and it is worth reading before assuming the problem is a character issue rather than a physiological one.

What the First Week Actually Feels Like

Honesty is more useful here than reassurance. In a medically managed detox, the first three to five days off short-acting opioids are physically miserable for most people: sweating and chills alternating, restless legs, a gut that will not settle, and almost no real sleep. When chronic pain is in the picture, add the specific complaint people voice most on day two, which is that their original pain site is now screaming. A person with lumbar disc disease will say their back has never been this bad. It is not imagined and it is not permanent.

What changes the week is what the medical team does with it. Comfort medications for nausea, cramping, and autonomic symptoms. Non-opioid analgesia where it is appropriate. Position changes, heat, gentle movement rather than bed rest, and a nursing staff that treats a 3 a.m. pain report as clinical information instead of drug-seeking. By roughly day five to seven, most people describe the withdrawal layer peeling off and the underlying pain becoming a defined thing again — still there, but no longer amplified by a nervous system in crisis. That distinction, felt rather than explained, is often the first moment a person believes treatment might work.

The Fear That Keeps People Out of Treatment

The most common reason people with chronic pain delay care is not denial. It is a specific and rational fear: that a treatment program will take away the only thing that lets them function and hand them a worksheet in return. Some have already had that experience somewhere else.

A program should be able to answer that fear directly at the assessment call, before admission. What is your approach to pain? Will there be a physician involved in pain management, not just addiction treatment? What happens if my pain is worse in week two? Who coordinates with my orthopedist or rheumatologist while I am here? Anyone can ask these questions of our admissions team at (877) 328-1968. A program that cannot give concrete answers is probably not the right setting for this presentation.

Medications That Can Address Both Problems

Medication decisions belong to a prescriber who has examined the person, so what follows is orientation, not a recommendation. Buprenorphine is often central to this conversation because it treats opioid use disorder and has analgesic properties of its own, which means for some people it addresses both targets with one medication. Dosing for pain can differ from dosing for use disorder alone, and the transition has to be timed carefully against the last opioid dose.

Naltrexone is a different tool entirely — it blocks opioid effects and offers no analgesia, so pain has to be covered by other means before it makes sense. Beyond opioid-specific medications, prescribers frequently build a non-opioid regimen from options used in chronic pain care generally, including certain antidepressants and anticonvulsants that act on nerve pain, topical agents, and scheduled non-opioid analgesics. The American Society of Addiction Medicine publishes clinical practice guidance on opioid use disorder treatment that informs how programs structure these decisions.

Non-Medication Pain Care That Earns Its Place

Some of what gets offered as holistic pain management is filler; the test is whether it changes what a person can actually do. Graded movement and physical therapy address the deconditioning that years of pain-driven inactivity produce, and deconditioning is itself a pain generator. Sleep restoration matters enormously, because pain tolerance drops sharply after poor sleep and poor sleep is nearly universal in early recovery. Cognitive behavioral approaches adapted for chronic pain target the catastrophizing loop — the jump from “this hurts” to “this will never improve and my life is over” — which measurably affects how disabling pain feels.

Trauma treatment belongs on this list too. A significant share of people with long-standing pain also carry post-traumatic stress, and the two amplify each other through a shared nervous system. Programs that integrate mental health treatment with addiction care are addressing both rather than sequencing them years apart.

When Other Substances Are Also in the Picture

Chronic pain rarely travels alone. Alcohol is a very common addition, used for sleep or for the hours when the prescription has worn off, and benzodiazepines are frequently co-prescribed for muscle spasm or anxiety. This changes the medical picture in a way that cannot be improvised at home. Withdrawal from alcohol and from benzodiazepines carries a risk of seizures, and in severe cases can be life-threatening — unlike opioid withdrawal, which is agonizing but not usually dangerous on its own. Anyone drinking heavily every day, or taking a benzodiazepine regularly, needs medically supervised withdrawal with a physician-directed taper. Stopping abruptly, or tapering without supervision, is the scenario that puts people in an emergency room. SAMHSA operates a free, confidential national helpline that can direct anyone to medically supervised options in their area, and the CDC publishes public guidance on opioid prescribing and overdose prevention.

One more safety point that applies to everyone in this group: tolerance falls fast after a period without opioids, so a return to a previously normal dose carries serious overdose risk. Naloxone should be in the house, and the people around the person should know where it is and how to use it.

What Families Notice

Families here often describe years of not knowing what they were looking at. The person was in pain, so the sleeping, the irritability, and the careful attention to refill dates all had an explanation. What families report noticing in hindsight is narrowing — fewer activities, fewer people, more of the day organized around medication timing — and a defensiveness that appeared only around that one subject.

The instinct to police the pill bottle is understandable and almost never productive. What helps more is being clear about what you have observed without diagnosing it, staying connected, and being informed enough about residential treatment to answer questions when the person is finally ready to ask them.

Building a Plan That Holds After Discharge

Residential treatment stabilizes this presentation; it does not finish it. A discharge plan for someone with chronic pain has to name specifics: who prescribes going forward, what the pain regimen is and who adjusts it, what the plan is for a flare, which specialists are involved and whether they are communicating with each other, and what happens if surgery becomes necessary later. Leaving without those answers means solving a medical problem alone under pressure, which is the circumstance that started this.

If you are weighing residential care for yourself or someone in your family, our team can talk through the clinical picture, coverage, and whether this level of care fits — call (877) 328-1968 or check your benefits through our insurance verification page.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Decisions about opioid medications, tapering, and pain management should be made with a qualified clinician who knows your history. If you are experiencing a medical emergency, or you suspect an overdose, call 911.

Adderall Withdrawal

Most people who develop a problem with prescription stimulants did not set out looking for a high. They started with a prescription that worked, or a roommate’s Adderall during finals week, or a job that seemed to demand more hours than a human body has. The progression is gradual enough that it is genuinely hard to see from the inside, and that is part of why prescription stimulant use disorder tends to arrive at our door later than it should.

What Prescription Stimulant Use Disorder Actually Looks Like

The prescription stimulants involved are usually amphetamine-based (Adderall, Vyvanse, Dexedrine) or methylphenidate-based (Ritalin, Concerta). What changes over time is rarely the drug and almost always the relationship to it.

In clinical intakes, the pattern people describe is remarkably consistent. The dose that used to carry an eight-hour workday stops carrying it. A second dose gets added in the afternoon, then a third in the evening, and the prescription that was written for thirty days runs out on day nineteen. That shortfall creates its own problem: a week of forced abstinence at the end of every month, which people experience as a crash so unpleasant that avoiding it becomes a motive of its own.

Route of use often shifts too. Crushing and insufflating tablets, or moving to intravenous use, changes both the pharmacology and the medical risk profile considerably. When someone discloses that during an assessment, it moves the conversation immediately toward medical evaluation rather than counseling alone.

The Line Between a Prescription and a Problem

Families and clients both ask where the line is. There is no single blood test or score that settles it, but clinicians look at a recognizable cluster: taking more than prescribed, running out early, obtaining pills from sources other than the prescriber, using to perform rather than to function, unsuccessful attempts to cut back, and continuing despite clear harm to sleep, weight, relationships, or cardiac health.

The National Institute on Drug Abuse maintains accessible overviews of prescription stimulant misuse and its health consequences, and it is a reasonable starting point for anyone trying to understand the difference between therapeutic use and a use disorder. See NIDA for that background.

One detail worth naming: having a legitimate diagnosis does not protect someone from developing a use disorder, and having a use disorder does not mean the original diagnosis was fake. Both can be true at once, and treating them as mutually exclusive is one of the more common ways people get stuck.

Prescription Stimulants Are Rarely the Only Substance Involved

By the time someone reaches residential care, stimulants are usually not the whole picture. Sleep becomes impossible on a high stimulant load, so people reach for something to come down: alcohol most often, sometimes benzodiazepines, sometimes cannabis. That secondary use is not a side note. It changes what a safe withdrawal looks like.

This is the point where self-managed detox becomes dangerous. Stopping stimulants abruptly is physically uncomfortable but not typically life-threatening. Stopping alcohol or benzodiazepines abruptly is a different matter: both carry a real risk of seizures and, in the case of alcohol, delirium tremens. Anyone who has been drinking heavily or taking benzodiazepines daily needs medically supervised withdrawal, not willpower and a quiet weekend. If that describes your situation or your family member’s, please call us at (877) 328-1968 before making any changes on your own.

A thorough intake also screens cardiovascular status. Sustained high-dose stimulant use is associated with hypertension, tachycardia, and in some cases cardiac complications, which is one reason a medical assessment belongs at the front of the process rather than somewhere in week two.

What the First Week Actually Feels Like

People arriving off prescription stimulants often expect the first week to be dramatic. Usually it is the opposite, and that surprises them.

The dominant experience is flatness. Sleep tends to come first and come hard, sometimes twelve or fourteen hours at a stretch for the first two or three days, and it can then flip into fragmented insomnia. Appetite returns, sometimes forcefully. Concentration is poor. Most notably, the world stops being interesting: anhedonia is the symptom clients name most often, and it is the one most likely to make someone want to leave.

Low mood in this window deserves genuine clinical attention rather than reassurance. Depressive symptoms during stimulant withdrawal can be significant, and passive suicidal thinking is not rare, which is why monitoring is built into residential care rather than left to chance. It also usually lifts. Telling someone on day four that their brain will feel like theirs again is a claim we can make honestly, provided we are also honest that the timeline is measured in weeks rather than days and varies by person.

Treating the ADHD Question Honestly

This is the conversation people are most anxious about: if the stimulant was treating something real, what happens now?

The clinically defensible answer is that the question cannot be answered accurately while someone is actively misusing. Attention, mood, and executive function all look impaired during withdrawal regardless of whether an underlying attention disorder exists. Reassessment generally waits for a period of stability, and it belongs to a prescriber who has the full history.

Non-stimulant options exist, and behavioral strategies for attention and organization work whether or not medication is part of the eventual plan. Any specific medication decision is between a client and their prescriber. The National Institute of Mental Health publishes plain-language material on ADHD and co-occurring conditions that families often find useful while they wait for that reassessment. Where a co-occurring diagnosis is confirmed, integrated mental health treatment runs alongside substance use care rather than after it.

What Families Tend to Notice First

Families rarely report the pills. They report the pattern around them: weight loss they cannot explain, a person who is up at three in the morning reorganizing a closet, irritability that has replaced a personality, a monthly cycle of a few flat exhausted days that everyone has learned to work around. Dental problems and skin picking show up too.

If you are the family member reading this, the most useful thing you can bring to an assessment is specific observation rather than diagnosis. Dates, amounts if you know them, and what changed. That detail shapes a treatment plan far more than a label does.

The Clinical Work After Stabilization

There is currently no medication approved to treat stimulant use disorder the way buprenorphine or naltrexone are used for opioid use disorder. Treatment is therefore behavioral, and the behavioral approaches with the strongest research support are structured rather than improvised: contingency management, cognitive behavioral therapy, and structured stimulant-specific programming.

In a residential treatment setting, that work is paired with the practical things that make early recovery survivable: a sleep schedule that is actually enforced, meals, exercise, and a daily structure that does not depend on chemical energy. Clients who have organized their working lives around stimulants often find the schedule itself is the intervention.

The Substance Abuse and Mental Health Services Administration publishes guidance on levels of care and on evidence-based practices for stimulant use, and its treatment locator is a useful reference for comparing options in your area.

When Residential Care Is the Right Level

Residential care is not the answer for every person misusing prescription stimulants. It becomes the appropriate level when outpatient attempts have not held, when there is concurrent alcohol or benzodiazepine dependence requiring supervised withdrawal, when psychiatric symptoms need daily monitoring, when there is stimulant-induced psychosis, or when the home environment makes abstinence unrealistic.

Our admissions team can talk through which level of care fits and what your coverage looks like. You can reach us at (877) 328-1968 or start with our insurance verification page. Ask about medical detox capability, whether psychiatric care is on site, and how the program handles ADHD reassessment. Those three answers tell you a great deal about whether a program is equipped for this specific problem.

A Note on What Recovery Looks Like Here

The people who do well are usually not the ones who arrive convinced. They are the ones who stay past the flat week. Cognitive clarity and motivation return unevenly, and expecting a straight line sets people up to read a hard Thursday as failure. It is more accurate, and more useful, to expect gradual and uneven improvement over the first several weeks.

If you are somewhere in the middle of this, whether it is your own use or someone you love, the decision in front of you is not a lifelong commitment. It is one assessment.

Educational Disclaimer

This article is for general educational purposes and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional, and no outcome is guaranteed. Do not stop or change any prescribed medication without speaking to your prescriber. Withdrawal from alcohol and benzodiazepines can be medically dangerous and requires supervision. If you are experiencing a medical emergency, call 911. If you are having thoughts of suicide, call or text 988 to reach the Suicide and Crisis Lifeline.

San Francisco Bay Area addiction treatment consulting and program placement | Bodhi nationwide network

Most people who come to residential treatment for opioid use disorder have already tried to stop on their own, often many times. They know the arc by heart: a rough first night, two days of bone aches and cold sweats, then a third day when the only thought still functioning is the one about relief. The return to use that follows rarely feels like a decision.

What many people have never been told is that medication can change the shape of that arc, and that starting it under medical supervision inside a structured program is nothing like trying to manage it alone. Medications for opioid use disorder, sometimes shortened to MOUD or MAT, come up in nearly every admissions call we take, and they remain among the most misunderstood parts of addiction care.

What MOUD Is, and What It Is Not

Three medications are approved in the United States for opioid use disorder: buprenorphine (often dispensed in combination with naloxone), naltrexone, and methadone. They work in very different ways. Buprenorphine and methadone occupy the same receptors that opioids do, which quiets withdrawal and craving without producing the same intensity of effect. Naltrexone does the opposite, blocking those receptors so that opioids produce little or nothing.

Both the National Institute on Drug Abuse and the Substance Abuse and Mental Health Services Administration describe these medications as evidence-based treatment for opioid use disorder, not as a lesser alternative to abstinence-based care. That framing matters, because the objection we hear most often is some version of trading one addiction for another. The concern deserves a real answer rather than a dismissal. Physical dependence and addiction are not the same thing. A prescribed, stable dose that does not produce intoxication, does not escalate, and does not organize a person’s whole day around obtaining it looks nothing like the pattern that brought them to treatment. Many people describe the difference simply: the noise stops.

The First Week on Buprenorphine

The most counterintuitive part of starting buprenorphine is that a person needs to be in withdrawal before the first dose. Because buprenorphine binds tightly to opioid receptors, taking it while other opioids are still present can displace them abruptly and set off precipitated withdrawal, which is worse than what the person walked in with. So clinical staff wait, and they measure. Withdrawal is scored on a structured scale, and the specific signs matter: gooseflesh on the forearms, pupils widening, yawning that will not stop, restless legs that make sitting through a group impossible.

When the timing is right, the first dose often works quickly. People frequently describe something settling within half an hour to an hour, and the description tends to be understated rather than dramatic. The aches back off. The sweating stops. Someone who could not sit still for ten minutes eats a full meal that afternoon.

The following days are less about relief and more about calibration. Doses are adjusted, sometimes several times, until cravings are quiet and the person is not sedated. Constipation is common and gets treated. Sleep is usually the last thing to come back, and it may take weeks rather than days. This is one reason a residential setting helps: adjustments happen with a nurse in the building rather than at an appointment two weeks out. Potent fentanyl analogs in the drug supply have also made induction less predictable, and some people need a longer waiting window or a modified approach. That is a clinical judgment call, not something to attempt at home.

Naltrexone: A Longer Runway, a Different Decision

Naltrexone appeals to people who want no opioid in their system at all, and for some it is the right fit. The obstacle is the gap it requires. Because naltrexone blocks receptors, it cannot be started until a person has been off opioids long enough to clear them, commonly a week or more depending on what was used, and starting too early can trigger significant withdrawal. Very few people can hold that gap open by themselves. A residential stay is often what makes it possible at all.

Naltrexone does not relieve withdrawal, so the days before the first dose are managed with supportive medications for nausea, muscle aches, anxiety, and sleep. Once it is in place, usually as a monthly extended-release injection, people tend to report that cravings are quieter and less interesting. The thought still arrives; it just has less pull. Liver function is monitored, and anyone with significant pain problems needs a plan in advance, since standard opioid pain control will not work normally while the medication is active.

Methadone, and Why Access Looks Different

Methadone remains an effective option, particularly for people with long histories of high-dose use, but it is dispensed through federally regulated opioid treatment programs rather than prescribed like other medications. In practice that means coordination: a residential program works with a licensed opioid treatment program for dosing, and the discharge plan has to include a receiving clinic before the person leaves. When someone arrives already stable on methadone, the goal is continuity. Stopping an established dose because a person changed levels of care is a preventable setback.

Sorting out which option fits your situation, or a family member’s, is a conversation worth having with clinicians rather than the internet. You can reach our admissions team at (877) 328-1968.

What Families Notice in the First Month

Families often expect medication to produce a visible transformation and are unsettled when week one sounds flat instead. Phone calls are short. The person sounds tired, sometimes irritable, not especially grateful. That is usually what stabilization looks like from the outside, not a sign of failure. Affect returns in the second and third weeks, in small ways: a joke on the phone, a question about someone else’s life, an actual opinion about dinner.

The other thing families raise is the fear that medication is a loophole, a way to feel better without changing anything. The honest answer is that medication makes change possible without guaranteeing it. It reduces the physiological pressure that makes therapy, accountability, and rebuilt routines nearly impossible to sustain. It does not do those things on its own, and no clinician should promise that it will.

Medication Is One Part of the Day, Not the Whole Plan

Inside residential treatment, the medication visit is a small part of the schedule. The rest is individual therapy, process groups, relapse-prevention skills, work on trauma when a person is stable enough for it, family sessions, and case management aimed at the practical wreckage: employment, housing, court dates, custody. The American Society of Addiction Medicine frames medication as one component within a level of care matched to a person’s overall needs, and that is roughly how it feels from the inside. Medication makes the day workable. The day is where the change happens.

Length of stay is matched to the person rather than a fixed template, and most plans step down rather than stop. An outpatient program with continued medication management is a far more durable ending than a discharge date and a phone number.

Safety Issues Worth Saying Plainly

Three points deserve emphasis. First, tolerance drops fast during any period away from opioids, which means that a return to a previously familiar amount can be fatal. Anyone leaving treatment, and their family, should have naloxone on hand and know how to use it. This is not a statement of expectation; it is basic preparation.

Second, opioid use rarely travels alone. Many people are also using alcohol, benzodiazepines, or both. Withdrawal from alcohol and from benzodiazepines can cause seizures and delirium and can be life-threatening, unlike opioid withdrawal, which is agonizing but not usually dangerous in itself. Those withdrawals require medical supervision and a structured taper. Nobody should attempt them alone or on a self-designed schedule, and a program needs to know about every substance involved before detox begins.

Third, stimulant use alongside opioids is increasingly common, and there is no approved medication for stimulant use disorder, so that side of the plan relies on behavioral treatment. Say what you are actually using at intake. Accurate information is what makes a safe plan possible.

Where to Start

There is no single correct medication. The decision is a shared one, shaped by history, other medical conditions, pain, prior attempts, and what a person is willing to sustain. It also does not need to be settled before anyone asks for help. Most people work it out in the first days of care, with a physician in the room.

If cost is what is holding you back, you can verify your insurance benefits before committing to anything, or call (877) 328-1968 and ask. It is a short conversation and it costs nothing.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Decisions about medications for opioid use disorder should be made with a qualified healthcare professional who knows your history. Withdrawal from alcohol or benzodiazepines can be medically dangerous and requires supervision. If you are experiencing a medical emergency, call 911.

Clinician meeting with a patient during cocaine and alcohol residential detox intake at a Santa Cruz treatment center

Most people who come to us for benzodiazepine problems did not set out to misuse anything. They were prescribed alprazolam, clonazepam, lorazepam, or diazepam for panic attacks, insomnia, or a stretch of acute stress, and the medication worked. Then it worked a little less. Then the dose that used to carry them through the day stopped carrying them past lunch. By the time they call us, many have already tried to stop on their own at least once, and the experience frightened them badly enough that they never tried again.

That fear is not irrational. Benzodiazepine withdrawal is one of the few forms of substance withdrawal that can be medically dangerous, and it deserves the same seriousness we give alcohol withdrawal. This article explains why a supervised taper matters, what the process actually looks like inside a Northern California residential program, and what families should expect to see.

Why Benzodiazepine Withdrawal Carries Real Medical Risk

Benzodiazepines amplify the effect of GABA, the brain’s main inhibitory neurotransmitter. Taken daily over months or years, the nervous system adapts: it dials down its own calming machinery because a medication is doing that job. Remove the medication abruptly and the brain is left with the adaptation but not the drug, which means excitation without a brake.

In practical terms, abrupt discontinuation after sustained use can produce grand mal seizures, delirium, dangerous blood pressure and heart rate swings, and in rare cases death. This is why we say plainly, and repeat it to every family that asks: benzodiazepine withdrawal, like alcohol withdrawal, carries seizure risk and requires medical supervision. It is not a matter of willpower, and it is not something to attempt alone at home. The National Institute on Drug Abuse maintains general guidance on prescription sedative use and the hazards of stopping without clinical support.

What the First Week Actually Looks Like

Sleep usually goes first. People describe surfacing at two or three in the morning with a pounding heart and no obvious reason for it, then lying awake until the hallway lights come on. The sensory world gets louder. A fluorescent fixture that nobody else notices feels aggressive. A door closing down the corridor lands like a slap.

Other things we see routinely in week one: tension that settles in the jaw and the tops of the shoulders and will not release; a fine tremor most visible when someone lifts a coffee cup; a metallic or bitter taste; skin that feels oddly sensitive to fabric; appetite that drops off entirely for a few days.

The anxiety of benzodiazepine withdrawal is distinctive because it is untethered. It is not anxiety about a job or a marriage. It arrives without content, peaks, and recedes. Clients describe it as waves and windows: hours of feeling all right, then a stretch where everything is hard again. Knowing that pattern in advance helps.

Why We Taper Rather Than Stop

The clinical answer to physical dependence on a sedative is not removal. It is a gradual, structured reduction that lets the nervous system recalibrate at a rate it can tolerate. In many cases that means cross-tapering from a short-acting agent to a longer-acting one, which smooths out the peaks and troughs between doses, and then stepping the dose down in small, planned decrements with hold periods in between.

How fast is individual. It depends on the medication, the daily dose, how long someone has been taking it, whether alcohol or opioids are also involved, and how the person’s body responds to the first reductions. A taper that is appropriate for one person can be far too aggressive for another. The American Society of Addiction Medicine publishes clinical practice guidance that informs how programs approach sedative dependence, and any credible provider will individualize the schedule rather than apply a fixed timetable.

What a Residential Taper Looks Like Day to Day

Inside residential treatment, the taper runs underneath everything else. Vital signs are checked on a schedule. Withdrawal symptoms are rated at intervals so that a trend, not a single bad afternoon, drives dose decisions. Medications are dispensed at set times, which matters more than it sounds: the ritual of watching the clock for the next dose is part of what has to be unlearned.

We also pace the therapeutic work deliberately. Cognitively demanding therapy is difficult during active dose reduction, when concentration and memory are genuinely impaired. Trauma processing is generally not front-loaded. Early sessions focus on orientation, coping skills, and simply getting through the day. The deeper work comes when the person has the cognitive bandwidth to do it and keep it.

If you are trying to figure out whether this level of care is what your situation calls for, our admissions team will talk it through without a sales pitch. Call (877) 328-1968.

The Anxiety Underneath the Medication

Almost everyone tapering off a benzodiazepine was prescribed it for something real. Panic disorder, generalized anxiety, insomnia, post-traumatic stress. As the medication comes down, the original condition tends to become visible again, sometimes for the first time in years. Treating the dependence without treating what is underneath it is how people end up back on a prescription within months.

So the taper runs alongside mental health treatment: cognitive behavioral work for anxiety and for insomnia specifically, skills for tolerating physical sensations that used to be medicated away, and psychiatric consultation about non-sedative options where those are clinically appropriate. The National Institute of Mental Health provides general public information on anxiety disorders and the range of evidence-based treatments available.

When Alcohol Is Also in the Picture

Benzodiazepines and alcohol act on overlapping systems, and people who use both often do not present the combination clearly at intake, sometimes because they have not thought of the drinking as part of the problem. It matters a great deal clinically. Combined sedative dependence raises the stakes of withdrawal, and both substances independently carry seizure risk. If both are present, medically supervised withdrawal is not a recommendation; it is a requirement.

Our alcohol detox program near Santa Cruz and our benzodiazepine protocols are managed by the same clinical team for exactly this reason. Please be candid at assessment about everything you are taking, including how much you drink and any medication borrowed from a friend or family member. Nobody is going to be judgmental about it, and the information directly changes how safely we can manage the first week.

Protracted Symptoms and Realistic Timelines

Some people feel substantially better within a few weeks of completing a taper. Others report symptoms that linger, most commonly sleep disturbance, intermittent anxiety, and sensitivity to stress, over a longer period. Research on protracted withdrawal is still developing and individual experience varies widely, so we avoid promising a timeline we cannot guarantee.

What we can say is that lingering symptoms generally trend downward, that they respond to sleep regulation and continued therapy, and that they are not a sign the taper was done wrong. SAMHSA offers general resources on recovery support and locating treatment, including its national helpline. Building a step-down plan before discharge, whether that is outpatient care, ongoing therapy, or a peer support group, is the single best predictor we see of how the first six months go.

What Families Actually Notice

Families rarely describe the clinical symptoms. They describe irritability that seems out of proportion to whatever triggered it, a partner who wants the television off and the curtains closed, someone who cancels plans repeatedly, and a person who seems physically present but hard to reach in conversation. These are ordinary features of a taper, not evidence that someone is doing badly.

Two practical requests. First, do not negotiate the taper schedule at home. Dose decisions belong to the clinical team, and a family argument about whether to speed things up puts everyone in an impossible position. Second, know the emergencies: a seizure, marked confusion about time or place, a high fever, or a sudden loss of consciousness means calling 911 immediately. If someone in your family is currently taking a benzodiazepine daily and is talking about quitting cold turkey this weekend, treat that as urgent and get clinical advice first.

Starting the Conversation

To talk with our admissions team about a medically supervised taper in Northern California, call (877) 328-1968. We can usually tell you in one conversation whether residential care is the right level, or point you somewhere more appropriate if it is not.

Educational Disclaimer

This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for consultation with a qualified healthcare professional. Never start, change, or stop a prescribed medication, including a benzodiazepine, without direct medical supervision. If you are experiencing a medical emergency, call 911. Reviewed September 6, 2026.

Nurse reviewing medical records at a computer during an overnight shift in a residential detox unit

Kratom, a plant-derived compound sold widely in the United States as a supplement, has moved rapidly from a niche substance into a common reason people seek medical detox. Its active alkaloids act on the same opioid receptors as prescription opioids, and daily use for even a few months can produce physical dependence that mirrors a short-acting opioid. When a person tries to stop abruptly, the withdrawal syndrome is often more intense than they expected and drives return to use within a day or two. At Bodhi Addiction Treatment and Wellness in Northern California, our medical team has treated a steady rise in kratom detox admissions and structures care specifically for this substance.

This article covers why kratom produces true physical dependence, what the withdrawal timeline actually looks like, which medications we use in a residential setting, and why finishing detox alone rarely leads to lasting recovery.

Why Kratom Produces Real Physical Dependence

Kratom’s primary alkaloids, mitragynine and 7-hydroxymitragynine, are partial agonists at the mu-opioid receptor. At lower doses they produce stimulant-like effects; at higher doses they produce opioid-like sedation and analgesia. The National Institute on Drug Abuse reports that repeated use leads to tolerance, physical dependence, and a discontinuation syndrome comparable in symptom profile to opioid withdrawal.

Because kratom is legal in most states and marketed as a natural supplement, many people minimize its dependence potential until they try to stop. Daily users who take multiple grams several times a day, or who use extract products with concentrated 7-hydroxymitragynine, are the group most likely to require medical detox rather than a taper at home. The FDA has issued repeated warnings about the risks of unregulated kratom products, including contamination and highly variable potency between brands.

What the Withdrawal Timeline Actually Looks Like

Kratom withdrawal typically begins within twelve to twenty-four hours of the last dose and peaks between forty-eight and seventy-two hours. Common symptoms include muscle aches, restless legs, gastrointestinal distress, sweating, chills, insomnia, anxiety, irritability, and intense cravings. Some people also experience dysphoria, low mood, and cognitive fog that can persist for one to two weeks after physical symptoms resolve.

Compared with short-acting opioid withdrawal, kratom withdrawal is often shorter in duration but similar in intensity, particularly for high-dose daily users. The psychological component, especially the low mood and cravings, is what most often drives a return to use if the person is detoxing without support. Our related post on post-acute withdrawal syndrome covers the longer-tail symptoms that can linger after the acute phase.

Medications We Use in Residential Detox for Kratom

The evidence base for kratom detox medications comes largely from opioid detox protocols adapted for this population. Buprenorphine, a partial mu-opioid agonist itself, is the most effective medication for suppressing kratom withdrawal and is often initiated in a low-dose protocol during the first twenty-four hours. Some patients transition to a maintenance dose for weeks to months; others taper off within the residential stay depending on severity and personal preference.

For patients who prefer non-opioid symptom management, we use combinations of clonidine or lofexidine to reduce autonomic symptoms, ondansetron for nausea, hydroxyzine for anxiety and insomnia, and NSAIDs for muscle aches. The Substance Abuse and Mental Health Services Administration maintains treatment guidelines for opioid use disorder that inform our kratom protocols. See our overview of how our 5-day medical detox prepares you for residential rehab for the full flow.

Why Detox Alone Rarely Leads to Lasting Recovery

A common pattern with kratom is a short medical detox followed by relapse within days or weeks. This happens because detox addresses the physical dependence but not the reasons a person began using kratom in the first place, which are usually some combination of untreated pain, anxiety, depression, or a prior opioid use disorder that the person was self-managing with kratom. Discharging directly home after detox without a plan for those underlying issues sets the person up to return to use.

Residential treatment after detox at Bodhi typically runs thirty to ninety days depending on clinical need. During that time we address co-occurring anxiety and depression, teach non-pharmacological pain management for patients whose kratom use began as pain self-management, and build the coping skills that will need to replace the substance long-term. Our post on how to choose a residential rehab covers the questions worth asking any program.

What Sets Bodhi Apart for Kratom Detox

Bodhi is a licensed residential detox and treatment facility in Northern California with twenty-four-hour medical and nursing staff, on-site addiction medicine physicians, and a psychiatric provider integrated into the treatment team. Our environment is a small, home-like residential setting rather than a hospital, which most patients find easier to tolerate during the emotionally difficult early days of kratom withdrawal.

Because kratom detox admissions have grown steadily over the past several years, our clinical team has direct experience with the specific presentation of this substance, including patients using highly concentrated extract products who often require higher doses of medication than a typical opioid detox protocol would suggest. Read our related post on the Matrix Model for stimulant use disorder if your kratom use has occurred alongside stimulant use.

Getting Started at Bodhi

If you or a family member is using kratom daily and finding that stopping produces withdrawal symptoms that keep pulling you back, our admissions team can complete an assessment by phone and verify most PPO insurance benefits within an hour. Coverage for medical detox and residential treatment is typically included in behavioral health benefits under the Affordable Care Act’s essential health benefits.

Call Bodhi Addiction Treatment and Wellness at 877-328-1968 to speak with an admissions counselor, or visit our admissions page to begin the process online.